The UK’s National Institute for Health and Care Excellence (NICE) has issued further draft guidance reaffirming its decision ...

England’s National Institute for Health and Care Excellence (NICE) has given a second thumbs down to a pair of Alzheimer’s ...

Days after suffering a rejection in Australia, the Alzheimer’s drug hit another roadblock in the U.K., which found the drug ...

Systematic fraud -- led by a "cabal of self-interested researchers, government accomplices, and corporate greed" in the words ...

Heidi McWilliams, a 10-year Palm Beach resident, is chair of the organization's inaugural event at the Palm Beach County ...

Lantheus Holdings, Inc.'s stock soars 55%, fueled by Pylarify and strategic acquisitions in Alzheimer's and oncology. Click ...

NICE has upheld its decision not to recommend Alzheimer's treatments donanemab and lecanemab for NHS use, citing high costs ...

It's hard to argue with the kinds of results Eli Lilly (NYSE: LLY) has produced over the past five years. The company has ...

The Alzheimer's Drug Discovery Foundation (ADDF) marked its Inaugural ADDF Scientific Summit in a momentous celebration of ...

Eli Lilly says a new starting dose regimen for its Alzheimer's disease therapy Kisunla reduces the risk of side effects that have stood in the way of approvals and reimbursement decisions for ...

St. Charles, Missouri, resident Sue Bell became one of the first Alzheimer's patients in the U.S. to receive the drug now ...

There are now two fully approved drugs on the market that can, sometimes, slow down the progression of Alzheimer's disease.